Cancer Biomarker Array
Alpha-fetoprotein, CEA, NSE, PSA-total, CA125, Cytokeratin 19 (KRT19), Pepsinogen 1, SERPINB3 (SCCA1), CA15-3, GOLM1 (GP73), Pepsinogen 2, Thyroglobulin, CA19-9, hCG beta, ProGRP, CA72-4, HE4 (WFDC2), PSA-free
Serum, Plasma, Cell Culture Supernatant, Cell Lysates, Tissue Lysates, Other Body Fluids
Multiplex Protein Detection
Dry the glass slide
Block array surface
Incubate with Samples and Standards
Incubate with Biotinylated Detection Antibody Cocktail
Incubate with Streptavidin-Conjugated Fluor
Disassemble the glass slide
Scan with a gene microarray laser scanner
Perform densitometry and analysis
Antibody Array Slide
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Once thawed, please keep reagents under suitable conditions respectively. Do not use past expiration date.
A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum. While numerous challenges exist in translating biomarker research into the clinical space; a number of gene and protein based biomarkers have already been used at some point in patient care; including, AFP (Liver Cancer), BCR-ABL (Chronic Myeloid Leukemia), BRCA1 / BRCA2 (Breast/Ovarian Cancer), BRAF V600E (Melanoma/Colorectal Cancer), CA-125 (Ovarian Cancer), CA19.9 (Pancreatic Cancer), CEA (Colorectal Cancer), EGFR (Non-small-cell lung carcinoma), HER-2 (Breast Cancer), KIT (Gastrointestinal stromal tumor), PSA (Prostate Specific Antigen) (Prostate Cancer), S100 (Melanoma), and many others. Mutant Proteins themselves detected by Selected Reaction Monitoring (SRM) have been reported to be the most specific biomarkers for cancers because they can only come from an existing tumor.